What do systematic reviews say?

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Single‐dose, preoperative MMC‐EMDA vs TURBT alone

The review found no eligible studies for this question.

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Supervised exercise therapy following vascular intervention vs vascular intervention alone

• Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic peripheral… 2024 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 105 participants
  Very low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 946 participants
  Low

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found